NCT01069705 - Second Open Label Extension to Bridging Study CTBM100C2303 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2010

Primary Completion Date

March 19, 2012

Study Completion Date

March 19, 2012

Conditions

Pulmonary InfectionsPseudomonas Aeruginosa

Interventions

DRUG

Tobramycin inhalation powder

Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.

Trial Locations (17)

Novartis Investigative Site, Pleven

Novartis Investigative Site, Plovdiv

Novartis Investigative Site, Sofia

Novartis Investigative Site, Varna

Novartis Investigative Site, Tallinn

Novartis Investigative Site, Tartu

Novartis Investigative Site, Riga

Novartis Investigative Site, Kaunas

Novartis Investigative Site, Vilnius

Novartis Investigative Site, Bucharest

Novartis Investigative Site, Timișoara

Novartis Investigative Site, Kazan'

Novartis Investigative Site, Moscow

Novartis Investigative Site, Saint Petersburg

Novartis Investigative Site, Samara

Novartis Investigative Site, Yaroslavl

Novartis Investigative Site, Durban